Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
← catalyst calendarNCT06779630 · readout ≤ 407 d
Sponsored by Teleflex (industry) · TFX — their whole pipeline →. With BIOTRONIK AG (A Teleflex Company).
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
23
Countries
Austria, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-18 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Coronary Artery Disease
Intervention
- Device: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
Primary outcome
what the primary-completion date above is the date OFTarget Lesion Failure (TLF) rate at 12 months post-index procedure
measured 12 months
Permalink · TFX's whole pipeline · Catalyst calendar · Every registered study · What changed